• Current Issue:
    4articles Vol.2(2024) , Issue 6
    Sort by
    Latest
    Open Access
    Review
    Uricases: reflections on recent developments in the management of challenging gout patients
    Oral urate-lowering therapy (ULT) is key to treating gout. However, many patients receiving oral ULT do not achieve the target serum urate (SU) levels, partly because some patients cannot tolerate o [...] Read more.
    Naomi Schlesinger, Dan Kaufmann
    Published: October 02, 2024 Explor Musculoskeletal Dis. 2024;2:461–472
    DOI: https://doi.org/10.37349/emd.2024.00070
    This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout
    View:123
    Download:8
    Times Cited: 0
    Open Access
    Review
    CPPD—differential diagnostics and differential therapeutic challenges
    Calcium pyrophosphate deposition disease (CPPD), characterized by the presence of calcium pyrophosphate crystals in and around joints, poses diagnostic and therapeutic challenges in rheumatology. Th [...] Read more.
    Maria L. Voulgari, Herbert Kellner
    Published: September 25, 2024 Explor Musculoskeletal Dis. 2024;2:443–460
    DOI: https://doi.org/10.37349/emd.2024.00069
    This article belongs to the special issue Calcium Pyrophosphate Deposition Disease
    View:164
    Download:9
    Times Cited: 0
    Open Access
    Original Article
    Factors associated with interstitial lung disease in patients with rheumatoid arthritis
    Aim: Interstitial lung disease (ILD) is a significant extra-articular manifestation of rheumatoid arthritis (RA). The prevalence and risk factors for ILD in RA exhibit considerable variation. Thi [...] Read more.
    Benyapa Suppa-Udom ... Wanruchada Katchamart
    Published: September 14, 2024 Explor Musculoskeletal Dis. 2024;2:431–442
    DOI: https://doi.org/10.37349/emd.2024.00068
    View:154
    Download:9
    Times Cited: 0
    Open Access
    Perspective
    Selecting the best-value biosimilar in emerging countries
    The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cas [...] Read more.
    Gilberto Castañeda-Hernández
    Published: September 14, 2024 Explor Musculoskeletal Dis. 2024;2:423–430
    DOI: https://doi.org/10.37349/emd.2024.00067
    This article belongs to the special issue Biosimilars: State of the Art in the Treatment of Rheumatic Diseases
    View:171
    Download:12
    Times Cited: 0